Normal Pregnancy Clinical Trial
— GRAPLOfficial title:
Thrombophilia Assessment and Pregnancy: Determination of Reference Values for dRVVT in Pregnant Women
Pregnancy is associated with significant changes in several aspects of haemostasis, especially an imbalance between procoagulant and anticoagulant factors. These changes contribute to creating a state of hypercoagulability, mainly at the end of pregnancy and during the post-partum period, protecting pregnant women from delivery haemorrhage, but exposing them to a major thromboembolic risk. Vascular diseases of pregnancy (VDP) are obstetric diseases which are linked to an ischaemic origin associated with placental thrombosis. These include pre-eclampsia, retroplacental haematoma, intrauterine growth retardation and even foetal death in utero. A number of risk factors have been identified for these VDPs, some of which have extremely serious consequences, the main one being antiphospholipid syndrome (APS). The diagnosis of VDP in a current or previous pregnancy requires close monitoring and joint management by an obstetrician, haemostasis physician, internist and medical biologist, particularly in terms of pre, peri- and post-partum anticoagulation in patients at increased risk of thromboembolism. The aim of treating APS during pregnancy is : to reduce the occurrence of maternal arterial or venous thrombotic complications in one hand and in the other hand to reduce the occurrence of obstetric complications, which are responsible of a significant morbimortality rate. The detection of a possible APS during pregnancy will therefore determine the specific management of patients. The latest guidelines from the Groupe Français d'Etude sur l'Hémostase et la Thrombose (GFHT) in 2022 recommended a diluted Russell's viper venom time (dRVVT) and an activated partial thromboplastin time (APTT) measured using a sensitive reagent such as silica (SCT) should be used to assess the presence of LA.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | September 28, 2024 |
| Est. primary completion date | September 28, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 50 Years |
| Eligibility | Inclusion Criteria: Control group : - patients with normal pregnancies at the HCL. - Affiliation to a social security regime Case group : - Patients followed at the HCL who had an increased dRVVT ratio during pregnancy, investigated as part of the development of VDP during pregnancy. - Affiliation to a social security regime Exclusion Criteria: - History of thromboembolic disease - History of autoimmune disease - History of VDP |
| Country | Name | City | State |
|---|---|---|---|
| France | Dr Céline BAZIN | Lyon |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | dRVVT value during pregnancy. | Carrying out the dRVVT in the haemostasis laboratory of the Centre de Biologie et de Pathologie Est | through study completion, an average of 9 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00341263 -
Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies
|
||
| Completed |
NCT01907620 -
Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia.
|
N/A | |
| Completed |
NCT03692923 -
VIRTUAL COMMUNITY for PREGNANT WOMEN
|
N/A | |
| Recruiting |
NCT04400084 -
Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta
|
||
| Completed |
NCT04215484 -
Placenta Accreta New Detection Procedure by Rapid Assessment of Serum BNP
|
||
| Completed |
NCT00437996 -
Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial
|
Phase 3 |